Two supplements can contain the exact same milligrams of the same compound and behave completely differently in the body. The difference usually isn't the ingredient — it's what happens to that ingredient between the moment you swallow it and the moment it reaches your bloodstream. This is the problem liposomal delivery is built to solve, and it's worth understanding at the level of mechanism rather than marketing.
This is an explainer about absorption — how much of a dose survives digestion and enters circulation intact. It is not a claim about what any specific compound does once it gets there.
The Journey a Normal Supplement Has to Survive
When you swallow a standard tablet, powder, or capsule, the compound inside faces three obstacles before it can reach systemic circulation:
- Gastric acid. The stomach sits at a pH of roughly 1.5–3.5. Acid-labile molecules can be partially degraded here before they ever reach the intestine.
- Digestive enzymes. At the intestinal wall, brush-border enzymes can modify or break down molecules during uptake.
- First-pass metabolism. Compounds absorbed through the standard route enter the portal circulation and pass through the liver before reaching the rest of the body, where a fraction is metabolised away.
For some nutrients this attrition is minor. For others — particularly poorly soluble or chemically fragile molecules — the amount that actually reaches circulation can be a small fraction of the labelled dose. That gap between dose on the label and dose in the blood is what bioavailability measures.
What a Liposome Actually Is
A liposome is a microscopic vesicle: a spherical shell made of a phospholipid bilayer surrounding a watery core. It mirrors the same basic architecture as the membrane of your own cells — phospholipid heads facing outward toward water, fatty tails tucked inward.
That structure lets a liposome carry two kinds of cargo at once. Water-soluble compounds sit in the aqueous core; fat-soluble compounds embed within the bilayer itself. Vesicle size matters: functional liposomes generally operate in the ~50–200 nm range, which is the window where the intestinal lining can take them up efficiently.
Why the Phospholipid Shell Changes the Outcome
The phospholipid bilayer addresses the three obstacles above more or less simultaneously:
- It is more resistant to gastric acid, shielding the encapsulated compound through the stomach.
- It shields the cargo from brush-border enzymes during intestinal transit.
- At the intestinal epithelium, liposomes can be taken up via endocytosis — the cell membrane engulfs the whole vesicle — and a portion can enter through the lymphatic route, which partially bypasses immediate first-pass liver metabolism.
Mechanistic studies support each of these steps. Work on lipid-bilayer models and Caco-2 intestinal cell lines has been used to map how phospholipid-based systems cross the intestinal barrier (PMC8728740). A study on a phospholipid-complex delivery system for the poorly soluble compound silybin measured lymphatic transport substantially higher than the free compound, and a large increase in relative bioavailability — giving a concrete mechanistic picture of the lymphatic-uptake effect (PMC6882455).
The net effect: a larger fraction of the dose reaches systemic circulation intact compared with a conventional format of the same compound. That is an absorption property — not a promise about downstream effect.
How the Difference Is Measured
In a pharmacokinetic comparison, participants take the liposomal form and a comparator, and researchers track the compound's concentration in blood over time. Two numbers matter most:
- Cmax — the peak concentration reached.
- AUC (area under the curve) — the total exposure over time.
A formulation with a higher AUC delivered more of the compound into circulation over the measurement window. The size of that difference is entirely formulation-dependent. A double-blind, placebo-controlled, randomised trial of liposomal CoQ10 attributed its absorption differences specifically to the protection of the phospholipid bilayer and enhanced transmucosal uptake (Frontiers in Nutrition, 2025, article 1605033) — and a randomised crossover trial of liposomal multinutrients found improved short-term absorption of selected nutrients versus non-liposomal comparators (Journal of Functional Foods, 2025, S1756464625004451).
This is also why comparison shopping on bioavailability is meaningful only when the number comes from a head-to-head study of that formulation against a named comparator, at a stated dose. A figure with no comparator and no study behind it is a marketing claim, not a measurement.
LipoSone™ Bioavailability Data
| Formulation | Dose | AUC vs. Standard | Comparator |
|---|---|---|---|
| Liposomal Glutathione | 500 mg | 63.62× higher AUC | Standard tablet (same dose) |
| Liposomal Iron | 15 mg | 397.7× higher AUC | Standard iron powder (same dose) |
| Liposomal Iron | 15 mg | 44.4× higher AUC | Iron tablet + vitamin C (optimised standard) |
| Liposomal Curcumin | 250 mg | 46.79× higher AUC | Standard curcumin extract (same dose) |
Liposomal Glutathione
The Liposomal Glutathione RCT followed 20 participants (10 receiving liposomal glutathione, 10 receiving standard tablet glutathione) in a crossover design. Plasma glutathione was measured at baseline, 0.5 hours, 1 hour, 2 hours, 4 hours, and 7 hours post-dose. The AUC was 63.62 times higher for the liposomal form than the standard tablet at the same 500 mg dose.
Liposomal Iron
Liposomal Iron showed AUC 397.7 times higher than a standard iron powder comparator at the same 15 mg dose. When compared to a tablet formulation combined with vitamin C (a known iron absorption enhancer), the liposomal form still achieved 44.4 times higher AUC. This demonstrates that liposomal delivery outperforms even optimised standard formulations.
Liposomal Curcumin
Liposomal Curcumin achieved 46.79 times higher AUC than standard curcumin extract. Peak plasma concentration (Cmax) was reached at 2 hours for the liposomal form — significantly faster than standard formulations, which show delayed and lower peaks due to poor solubility and absorption.
Why Format Matters More Than Dose
A poorly absorbed compound at high dose delivers less systemic exposure than a well-absorbed compound at low dose. Format — the delivery vehicle — is the primary lever for bioavailability, not the amount of active ingredient listed on the label.
Consider the comparison for curcumin:
- Standard curcumin at 1,000 mg: Typical oral bioavailability 10–15% → ~100–150 mg absorbed
- LipoSone™ curcumin at 250 mg: 46.79× higher AUC than standard → substantially higher absorbed amount per mg dose
The absorbed amount — the amount that reaches systemic circulation — is what creates a measurable biological response. Dose listed on the label matters only insofar as the delivery system allows it to be absorbed.
This principle applies across all three LipoSone formulations. The standardised dose is not the “maximum amount to take” — it is the amount calibrated to the liposomal delivery system to achieve the maximum absorption per unit.
LipoSone™: Implementation Details
LipoSone™ uses sunflower-derived phosphatidylcholine (a plant-based phospholipid) to form the bilayer. Sunflower lecithin is non-GMO and soy-free — important because soy phospholipids can cross-react with soy allergies. LipoSone formulations are designed to be hypoallergenic.
Each formulation is manufactured in Germany in a GMP-certified facility. The liposomal suspension is bottled as a liquid (not a powder requiring reconstitution). Liquid liposomes are inherently more stable than powders and do not require additional encapsulation steps.
Daily serving sizes are calibrated to the liposomal payload — the doses at which bioavailability was measured in the respective RCTs:
- Glutathione: 7 mL per day (500 mg reduced L-glutathione)
- Iron: 5 mL per day (15 mg liposomal iron saccharate)
- Curcumin: 7 mL per day (250 mg curcumin)
Every batch undergoes third-party testing in independent European laboratories, confirming identity (the active is present), purity (contaminants below regulatory thresholds), and potency (dose matches the label).
The Liposomal Advantage: Three Problems Solved
Liposomal delivery solves three problems simultaneously:
- Protection from degradation. Glutathione survives the stomach intact. Curcumin solubility is no longer a barrier to absorption.
- Higher absorbed fraction. Bioavailability is not 10–30% — it is substantially higher, measured at 46.79× to 397.7× in published RCTs.
- Lower dose, higher systemic concentration. This reduces pill burden, lowers cost per unit of absorbed bioactive, and reduces the risk of interactions from consuming large tablet volumes.
The tradeoff is manufacturing complexity. A liposomal formulation requires precise control of phospholipid ratios, bilayer size, encapsulation efficiency, and stability over the product shelf life. It cannot be manufactured as a simple tablet press. This is why liposomal supplements cost more than standard tablets at the same listed dose — the format is the value, and the format is expensive to produce at clinical standards.
For compounds that are poorly absorbed in standard form, liposomal delivery is not a luxury. It is the practical ceiling on what oral supplementation can achieve.
Three Things Liposomal Delivery Does Not Change
- Not every compound needs it. Nutrients that already absorb well gain less from encapsulation. The format earns its place most with fragile or poorly soluble molecules.
- Formulation quality decides everything.Vesicle size, phospholipid purity, and the stability of the bilayer determine whether a liposome actually survives to the intestine or falls apart first. “Liposomal” on a label is not automatically functional.
- Absorption is not the same as outcome. Getting more of a compound into the blood is a delivery achievement. What that compound does in the body is a separate question governed by its own evidence.